TY - JOUR
T1 - Post-interventional adverse event risk by vascular access site among patients with acute coronary syndrome in Japan
T2 - observational analysis with a national registry J-PCI database
AU - for the J-PCI Investigators
AU - Fujii, Toshiharu
AU - Ikari, Yuji
AU - Hashimoto, Hideki
AU - Kadota, Kazushige
AU - Amano, Tetsuya
AU - Uemura, Shiro
AU - Takashima, Hiroaki
AU - Nakamura, Masato
AU - Shiode, Nobuo
AU - Tanaka, Nobuhiro
AU - Akasaka, Takashi
AU - Morino, Yoshihiro
AU - Fujii, Kenshi
AU - Hikichi, Hiroshi
AU - Fujii, Kenshi
AU - Kohsaka, Shun
AU - Ishii, Hideki
AU - Tanabe, Kengo
AU - Ozaki, Yukio
AU - Sumitsuji, Satoru
AU - Iida, Osamu
AU - Hara, Hidehiko
AU - Shirai, Shinichi
AU - Nanasato, Mamoru
AU - Inohara, Taku
AU - Ueda, Yasunori
AU - Numasawa, Yohei
AU - Noma, Shigetaka
N1 - Publisher Copyright:
© 2019, Japanese Association of Cardiovascular Intervention and Therapeutics.
PY - 2019/10/1
Y1 - 2019/10/1
N2 - This study evaluated whether radial access intervention had a lower risk of post-treatment adverse events in acute coronary syndrome (ACS) even in Japan where the use of a strong antithrombotic regimen was not approved. We retrospectively analyzed a large nation-wide registry in Japan to compare the incidence of post-treatment adverse events according to the types of vessel access (trans-radial; TRI vs. trans-femoral; TFI) among ACS cases (n = 76,835; 43,288 TRI group and 33,547 TFI group). Primary outcome was a composite of in-hospital death, myocardial infarction associated with percutaneous coronary intervention, bleeding complication requiring transfusion, and stent thrombosis during in-hospital stay. Propensity score matching (PS) and instrumental variable (IV) analyses were used to account for treatment selection. The incidence of post-treatment adverse events was lower in the TRI group by 0.95% compared to the TFI group with PS (p < 0.001) and by 0.34% with IV (p = 0.127). A significantly lower risk for access site bleeding was observed by 0.34% with PS (p < 0.001) and by 0.53% with IV (p < 0.001). Radial access was related to a significantly lower risk for access site bleeding compared with femoral access, even without strong antithrombotic drugs for ACS in Japan, and may also relate to lower risk for a wider set of post-treatment adverse events.
AB - This study evaluated whether radial access intervention had a lower risk of post-treatment adverse events in acute coronary syndrome (ACS) even in Japan where the use of a strong antithrombotic regimen was not approved. We retrospectively analyzed a large nation-wide registry in Japan to compare the incidence of post-treatment adverse events according to the types of vessel access (trans-radial; TRI vs. trans-femoral; TFI) among ACS cases (n = 76,835; 43,288 TRI group and 33,547 TFI group). Primary outcome was a composite of in-hospital death, myocardial infarction associated with percutaneous coronary intervention, bleeding complication requiring transfusion, and stent thrombosis during in-hospital stay. Propensity score matching (PS) and instrumental variable (IV) analyses were used to account for treatment selection. The incidence of post-treatment adverse events was lower in the TRI group by 0.95% compared to the TFI group with PS (p < 0.001) and by 0.34% with IV (p = 0.127). A significantly lower risk for access site bleeding was observed by 0.34% with PS (p < 0.001) and by 0.53% with IV (p < 0.001). Radial access was related to a significantly lower risk for access site bleeding compared with femoral access, even without strong antithrombotic drugs for ACS in Japan, and may also relate to lower risk for a wider set of post-treatment adverse events.
UR - http://www.scopus.com/inward/record.url?scp=85072513680&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85072513680&partnerID=8YFLogxK
U2 - 10.1007/s12928-019-00582-0
DO - 10.1007/s12928-019-00582-0
M3 - Article
C2 - 30847655
AN - SCOPUS:85072513680
SN - 1868-4300
VL - 34
SP - 297
EP - 304
JO - Cardiovascular Intervention and Therapeutics
JF - Cardiovascular Intervention and Therapeutics
IS - 4
ER -